Details of the Drug

General Information of Drug (ID: DM1N62C)

Drug Name

Quetiapine

Synonyms

quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2], [3]
Alcohol dependence	6C40.2	Phase 3	[4]

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

383.5

Topological Polar Surface Area (xlogp)

2.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-4 h [5]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability: The bioavailability of drug is 90% [5]
Clearance: The clearance of drug is 101.04 +/- 39.11 L/h [7]
Elimination: 73% of a dose was detected in the urine, and about 20% in the feces [8]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 7 hours [8]
Metabolism: The drug is metabolized via the liver [9]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.6791 micromolar/kg/day [10]
Vd: The volume of distribution (Vd) of drug is 10 +/- 4 L/kg [11]
Water Solubility: The ability of drug to dissolve in water is measured as 94 mg/mL [6]

Chemical Identifiers

Formula: C21H25N3O2S
IUPAC Name: 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
Canonical SMILES: C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
InChI: InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
InChIKey: URKOMYMAXPYINW-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5002
ChEBI ID: CHEBI:8707
CAS Number: 111974-69-7
DrugBank ID: DB01224
TTD ID: D0H7KF
VARIDT ID: DR00855
INTEDE ID: DR1376
ACDINA ID: D00575

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[12], [13], [1]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Solute carrier family 22 member 23 (SLC22A23)	DTMJK12	S22AN_HUMAN	Substrate	[14]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[16]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[17]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Solute carrier family 22 member 23 (SLC22A23)	DTP	SLC22A23	6.77E-02	-2.72E-02	-1.93E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Quetiapine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Aripiprazole.	Schizophrenia [6A20]	[75]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Iloperidone.	Schizophrenia [6A20]	[76]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Paliperidone.	Schizophrenia [6A20]	[76]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Molindone.	Schizophrenia [6A20]	[75]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Thiothixene.	Schizophrenia [6A20]	[75]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Amisulpride.	Schizophrenia [6A20]	[77]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Asenapine.	Schizophrenia [6A20]	[76]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Quetiapine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Quetiapine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[78]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[79]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Midostaurin.	Acute myeloid leukaemia [2A60]	[76]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[80]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Quetiapine and Oliceridine.	Acute pain [MG31]	[81]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[82]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[82]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Ivabradine.	Angina pectoris [BA40]	[83]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Bepridil.	Angina pectoris [BA40]	[76]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Dronedarone.	Angina pectoris [BA40]	[76]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Quetiapine and Amyl nitrite.	Angina pectoris [BA40]	[84]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[85]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Posaconazole.	Aspergillosis [1F20]	[86]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Levalbuterol.	Asthma [CA23]	[87]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Pirbuterol.	Asthma [CA23]	[88]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[76]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Quetiapine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[86]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Retigabine.	Behcet disease [4A62]	[76]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Cariprazine.	Bipolar disorder [6A60]	[75]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Quetiapine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[78]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Eribulin.	Breast cancer [2C60-2C6Y]	[76]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lapatinib.	Breast cancer [2C60-2C6Y]	[76]
Tucatinib	DMBESUA	Major	Decreased metabolism of Quetiapine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[86]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Bosutinib.	Breast cancer [2C60-2C6Y]	[76]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Quetiapine when combined with Acetylcholine.	Cataract [9B10]	[89]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[90]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[91]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[88]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[87]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[91]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[91]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[88]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[88]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Quetiapine and Dihydrocodeine.	Chronic pain [MG30]	[92]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Sevoflurane.	Corneal disease [9A76-9A78]	[76]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Probucol.	Coronary atherosclerosis [BA80]	[76]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Pasireotide.	Cushing syndrome [5A70]	[76]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Osilodrostat.	Cushing syndrome [5A70]	[76]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Quetiapine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[93]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Quetiapine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[86]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Quetiapine and Cyclandelate.	Dementia [6D80-6D8Z]	[84]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Quetiapine and OPC-34712.	Depression [6A70-6A7Z]	[75]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Clomipramine.	Depression [6A70-6A7Z]	[76]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Mepenzolate.	Digestive system disease [DE2Z]	[75]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Quetiapine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[94]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Quetiapine and Deutetrabenazine.	Dystonic disorder [8A02]	[95]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Ingrezza.	Dystonic disorder [8A02]	[76]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Quetiapine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[78]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Quetiapine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[86]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Quetiapine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[78]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Quetiapine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[78]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Quetiapine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[78]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Solifenacin.	Functional bladder disorder [GC50]	[76]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[76]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Quetiapine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[86]
Telaprevir	DMMRV29	Major	Decreased metabolism of Quetiapine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[86]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Quetiapine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[76]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Quetiapine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Quetiapine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[78]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[76]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Quetiapine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Quetiapine and Penbutolol.	Hypertension [BA00-BA04]	[84]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Quetiapine and Nebivolol.	Hypertension [BA00-BA04]	[84]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Quetiapine and Levamlodipine.	Hypertension [BA00-BA04]	[84]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Quetiapine and TAK-491.	Hypertension [BA00-BA04]	[84]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Quetiapine and Hydralazine.	Hypertension [BA00-BA04]	[84]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Quetiapine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[84]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[75]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Quetiapine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[78]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Quetiapine and ITI-007.	Insomnia [7A00-7A0Z]	[75]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Quetiapine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[76]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[76]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Quetiapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[83]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Crizotinib.	Lung cancer [2C25]	[96]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Quetiapine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[78]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Osimertinib.	Lung cancer [2C25]	[97]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Selpercatinib.	Lung cancer [2C25]	[83]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Hydroxychloroquine.	Malaria [1F40-1F45]	[98]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[76]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Quetiapine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[86]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Vemurafenib.	Melanoma [2C30]	[76]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and LGX818.	Melanoma [2C30]	[76]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Quetiapine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[83]
Danazol	DML8KTN	Moderate	Decreased metabolism of Quetiapine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[86]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Quetiapine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[99]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Quetiapine and Lasmiditan.	Migraine [8A80]	[100]
Exjade	DMHPRWG	Moderate	Increased metabolism of Quetiapine caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[78]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Quetiapine and Flibanserin.	Mood disorder [6A60-6E23]	[101]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Panobinostat.	Multiple myeloma [2A83]	[102]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Siponimod.	Multiple sclerosis [8A40]	[78]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Fingolimod.	Multiple sclerosis [8A40]	[76]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Quetiapine and Ozanimod.	Multiple sclerosis [8A40]	[103]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Romidepsin.	Mycosis fungoides [2B01]	[76]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Quetiapine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[86]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[76]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[76]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Phenindamine.	Nasopharyngitis [CA00]	[75]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Quetiapine and Metoclopramide.	Nausea/vomiting [MD90]	[104]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Quetiapine and Lorcaserin.	Obesity [5B80-5B81]	[105]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Quetiapine and Polythiazide.	Oedema [MG29]	[84]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[83]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lofexidine.	Opioid use disorder [6C43]	[76]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Quetiapine caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[78]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Quetiapine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[86]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Triclabendazole.	Parasitic worm infestation [1F90]	[76]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Quetiapine when combined with Opicapone.	Parkinsonism [8A00]	[106]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Pimavanserin.	Parkinsonism [8A00]	[76]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Quetiapine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[107]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Methylscopolamine.	Peptic ulcer [DA61]	[75]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[108]
Lefamulin	DME6G97	Major	Decreased metabolism of Quetiapine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[109]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Quetiapine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[86]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Degarelix.	Prostate cancer [2C82]	[83]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and ABIRATERONE.	Prostate cancer [2C82]	[83]
Enzalutamide	DMGL19D	Major	Increased metabolism of Quetiapine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Relugolix.	Prostate cancer [2C82]	[83]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[76]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Quetiapine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[110]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Quetiapine when combined with Neupro.	Restless legs syndrome [7A80]	[106]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Quetiapine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[78]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Quetiapine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[86]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Quetiapine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[83]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Quetiapine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[86]
Armodafinil	DMGB035	Minor	Increased metabolism of Quetiapine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[111]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Quetiapine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[76]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[76]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[83]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[76]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Quetiapine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[112]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Lenvatinib.	Thyroid cancer [2D10]	[76]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Quetiapine and Cabozantinib.	Thyroid cancer [2D10]	[83]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Quetiapine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[78]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Quetiapine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[76]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Quetiapine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[75]
-----------


⏷ Show the Full List of 136 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Hydrazine yellow	E00409	164825	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Quetiapine 25 mg tablet	25 mg	Oral Tablet	Oral
Quetiapine 100 mg tablet	100 mg	Oral Tablet	Oral
Quetiapine 400 mg tablet	400 mg	Oral Tablet	Oral
Quetiapine 200 mg tablet	200 mg	Oral Tablet	Oral
Quetiapine 300 mg tablet	300 mg	Oral Tablet	Oral
Quetiapine 50 mg tablet	50 mg	Oral Tablet	Oral
Quetiapine 50 mg tablet	50 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 200 mg tablet	200 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 300 mg tablet	300 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 150 mg tablet	150 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 400 mg tablet	400 mg	24 HR Extended Release Oral Tablet	Oral
Quetiapine 150 mg tablet	150 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 50).
3	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
4	ClinicalTrials.gov (NCT02362412) Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes. U.S. National Institutes ofHealth.
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	BDDCS applied to over 900 drugs
7	Huang X, Zhang S, Ma Y, Yang H, He C, Tian R, Mei H, Liu L, Zhang B: Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles. Drug Des Devel Ther. 2018 Dec 31;13:255-264. doi: 10.2147/DDDT.S182965. eCollection 2019.
8	Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):25-35. doi: 10.9758/cpn.2015.13.1.25.
9	Takahiro M, Haruo I, Toshihiko, I: Identification of Gemfibrozil Metabolites, Produced as Positional Isomers in Human Liver Microsomes, by On-line Analyses Using Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy J. Mass Spectrom. Soc. Jpn.. 2004 Jun 6;52(5):277-283.
10	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11	Quetiapine fumarate fda label
12	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
13	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
14	Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012 Apr;12(2):165-72.
15	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
16	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
17	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
18	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
19	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
29	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
30	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
31	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
32	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
33	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
34	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
35	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
36	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
37	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
38	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
39	Drug Interactions Flockhart Table
40	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
41	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
42	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
43	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
44	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
45	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
46	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
47	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
48	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
49	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
50	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
51	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
52	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
53	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
54	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
55	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
56	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
57	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
59	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
60	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
61	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
62	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
63	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
64	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
65	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
66	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
67	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
68	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
69	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
70	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
71	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
72	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
73	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
74	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
75	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
76	Canadian Pharmacists Association.
77	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
78	Cerner Multum, Inc. "Australian Product Information.".
79	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
80	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
81	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
82	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
83	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
84	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
85	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
86	DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
87	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
88	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
89	Multum Information Services, Inc. Expert Review Panel.
90	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
92	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
93	Product Information. Seroquel (quetiapine). Zeneca Pharmaceuticals, Wilmington, DE.
94	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
95	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
96	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
97	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
98	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
99	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
100	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
101	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
102	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
103	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
104	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
105	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
106	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
107	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
108	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
109	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
110	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
111	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
112	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.